Spoken Alpha
Barinthus Biotherapeutics plc.
Barinthus Biotherapeutics plc develops immunotherapeutic drug candidates for autoimmune and inflammatory diseases. The company's lead program, VTP-1000, uses its proprietary SNAP-TI platform to restore immune tolerance in celiac disease patients and is in Phase 1 clinical trials.
Barinthus Biotherapeutics plc is a Healthcare company operating in Biotechnology with a $30.2M market cap.
BRNS beat consensus EPS by 0.1% in Q2 FY2026, reported Aug 5, 2026.
Behavioral analysis
Disclosures
Extracted from SEC 10-K filing, 2026-08-30.
Transcripts
We index calls for roughly 3,000 US-listed companies. If you'd like us to add BRNS, reply to your welcome email and we'll prioritize it.
History
Executives who appear on this company's earnings calls in our corpus, with role and tenure sourced from SEC filings. Click any name for the full role timeline and call appearance history. Per-executive behavioral deviation metrics are available to research subscribers.
Peers
Sector peers tracked by Spoken Alpha. Each links to the same machine-readable IR surface — earnings calls, executives, and accountability scores.
API
The same data on this page is available as a machine-readable feed via the Spoken Alpha API. One call returns the IR URL, recent transcripts, and accountability scores for BRNS.
$ curl https://api.spokenalpha.com/v1/companies/BRNSFAQ
Spoken Alpha indexes BRNS's earnings call transcripts at https://spokenalpha.com/companies/BRNS. Each call links to attributed speakers and parsed analyst Q&A. Barinthus Biotherapeutics plc.'s own investor relations page is at https://investors.barinthusbio.com/.
Barinthus Biotherapeutics plc. (BRNS) operates in the Healthcare sector (Biotechnology industry).
| Period | Reported | EPS actual | EPS consensus | EPS surprise | Revenue actual | Revenue consensus | Rev. surprise | Source |
|---|---|---|---|---|---|---|---|---|
| Q2 FY2026 | 2026-08-05 | $-0.26 | $-0.28 | +7.1% | $0 | — | — | EODHD |
| Q1 FY2026 | 2026-04-29 | $-0.14 | $-0.28 | +50.0% | $0 | — | — | EODHD |
| Q4 FY2025 | 2026-03-19 | $-0.27 | $-0.39 | +29.8% | $0 | — | — | EODHD |
| Q3 FY2025 | 2025-11-06 | $-0.24 | $-0.39 | +38.5% | $0 | — | — | EODHD |
| Q2 FY2025 | 2025-08-06 | $-0.52 | $-0.29 | -79.3% | $0 | — | — | EODHD |
| Q1 FY2025 | 2025-05-06 | $-0.49 | $-0.36 | -36.1% | $0 | — | — | EODHD |
| Q4 FY2024 | 2025-03-17 | $-0.20 | $-0.37 | +45.4% | $-9.2M | — | — | EODHD |
| Q3 FY2024 | 2024-11-05 | $-0.21 | $-0.44 | +52.3% | $15.0M | — | — | EODHD |
| Q2 FY2024 | 2024-08-07 | $-0.43 | $-0.41 | -4.9% | $0 | — | — | EODHD |
| Q1 FY2024 | 2024-05-12 | $-0.40 | $-0.61 | +34.4% | $0 | — | — | EODHD |
| Q4 FY2023 | 2024-03-19 | $-0.45 | $-0.50 | +10.0% | $5.4M | — | — | EODHD |
| Q3 FY2023 | 2023-11-08 | $-0.37 | $-0.55 | +32.7% | $0 | — | — | EODHD |
| Q2 FY2023 | 2023-08-09 | $-0.62 | $-0.59 | -5.1% | $334.0K | — | — | EODHD |
| Q1 FY2023 | 2023-05-11 | $-0.48 | $-0.58 | +17.2% | $468.0K | — | — | EODHD |
| Q4 FY2022 | 2023-03-23 | $-0.57 | $-0.42 | -35.7% | $6.5M | — | — | EODHD |
| Q3 FY2022 | 2022-11-09 | $0.22 | $-0.52 | +100.0% | $6.2M | — | — | EODHD |
| Q2 FY2022 | 2022-08-08 | $0.43 | $-0.40 | +100.0% | $17.1M | — | — | EODHD |
| Q1 FY2022 | 2022-05-10 | $0.07 | $-0.31 | +100.0% | $15.0M | — | — | EODHD |
| Q4 FY2021 | 2022-03-24 | $-0.38 | $-0.58 | +34.5% | $-1.0K | — | — | EODHD |
| Q3 FY2021 | 2021-11-11 | $-0.13 | $-0.30 | +56.7% | $19.0K | — | — | EODHD |
Source: EODHD. BRNS reported actuals as published; sparse fields render as —.